Opinion

Video

TAR-200 Clinical Development Program in NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Can you briefly mention other ongoing phase 3 studies with TAR-200?
      Related Videos
      1 expert in this video
      BPH Management: Patient Outcome Evolution
      Final Thoughts and Clinical Trials in NMIBC
      Final Thoughts and Clinical Trials in NMIBC
      Uptake of New Treatments in Urology Practice
      Uptake of New Treatments in Urology Practice
      Patient Communication and Treatment Adherence in NMIBC
      Patient Communication and Treatment Adherence in NMIBC
      1 expert in this video
      Resective Surgery and Minimally Invasive Procedures For BPH
      Operationalizing TAR-200 and Other Delivery Systems in Practice
      Operationalizing TAR-200 and Other Delivery Systems in Practice
      Unmet Needs in NMIBC
      Unmet Needs in NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.